Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2012 16:05 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Northera(TM) (Droxidopa) Study 306B Meets Primary Endpoint

Northera™ Demonstrated Statistically Significant Improvement Over Placebo in Reduction of Dizziness/Lightheadedness at Week 1 (p=0.018), the Primary Endpoint, and Standing Blood Pressure at...
November 07, 2012 16:16 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Third Quarter 2012 Financial Results

CHARLOTTE, N.C., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the quarter and nine months ended September 30,...
November 06, 2012 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Results From Northera(TM) (droxidopa) Study in Spinal Cord Injury at the 23rd International Symposium on the Autonomic Nervous System

CHARLOTTE, N.C., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced results from a study of Northera™ (droxidopa) in hypotensive individuals...
September 04, 2012 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference

CHARLOTTE, N.C., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 14th Annual Rodman & Renshaw Global Healthcare Investment...
August 08, 2012 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference

CHARLOTTE, N.C., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference...
August 07, 2012 16:13 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Second Quarter 2012 Financial Results

CHARLOTTE, N.C., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the quarter and six months ended June 30, 2012. For the...
July 10, 2012 06:45 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Implement Corporate Reorganization

CHARLOTTE, N.C., July 10, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that its Board of Directors plans to promptly implement a corporate...
July 03, 2012 06:45 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Provides an Update on Northera(TM) (droxidopa) Regulatory Status and Development Program

CHARLOTTE, N.C., July 3, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received a written response from the U.S. Food and Drug Administration (FDA) to Chelsea's...
June 21, 2012 08:00 ET | Source: Chelsea Therapeutics

Combined Northera(TM) (droxidopa) Data From Two Phase 3 Trials Confirm Symptom Improvement in Patients With Neurogenic OH

CHARLOTTE, N.C., June 21, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced results from an integrated dataset of two phase 3 studies, Study 301 and Study...
June 07, 2012 16:16 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces $6 Million in Cost Saving Initiatives to Support Expanded Enrollment Initiatives for Northera Study and Extend Cash Runway Into Third Quarter 2013

Officers and Directors Agree to 25% Reduction in Compensation Approximately 35% of Remaining Employees to Transition to Part-Time Status Chelsea Eliminating All Performance Bonuses Until...